Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy

IMPORTANCE: Although PCSK9 inhibitors (PCSK9i) were approved in 2015, their high cost has led to strict prior authorization practices and high copays, and use of PSCK9i in clinical practice has been low. OBJECTIVE: To evaluate patient access to PCSK9i among those prescribed therapy. DESIGN, SETTING,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Cardiol
Egile Nagusiak: Navar, Ann Marie, Taylor, Benjamin, Mulder, Hillary, Fievitz, Eugene, Monda, Keri L., Fievitz, Anna, Maya, Juan F., López, J. Antonio G., Peterson, Eric D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2017
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5963012/
https://ncbi.nlm.nih.gov/pubmed/28973087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.3451
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak